Wart Corn Remover

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the removal of warts and corns. It is intended for use in patients seeking a topical treatment option for these common skin lesions.

Dosage and Administration

The affected area should be washed thoroughly with warm water. Soaking the wart in warm water for approximately 5 minutes is optional but may enhance the effectiveness of the treatment. After cleansing, the area must be dried thoroughly to ensure proper adhesion of the medicated plaster.

If necessary, the plaster may be cut to fit the size of the wart. The medicated plaster should then be applied directly to the wart. This application should be repeated every 48 hours as needed, with a maximum treatment duration of up to 12 weeks.

Contraindications

The product is contraindicated for use on irritated, infected, or reddened skin. It should not be applied to genital warts, facial warts, moles, birthmarks, or warts with hair growing from them. Additionally, the product is contraindicated for application on mucous membranes.

Contact with the eyes or face should be avoided; in the event of contact with the eyes, thorough rinsing with water is recommended.

Warnings and Precautions

For external use only. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

This product is contraindicated for use on irritated, infected, or reddened skin. It should not be applied to genital warts, facial warts, moles, birthmarks, or warts with hair growing from them. Additionally, it is not intended for application on mucous membranes.

Users are advised to discontinue use and consult a healthcare professional if discomfort persists or worsens. Furthermore, individuals with diabetes or poor blood circulation should seek medical advice prior to use to ensure safety and appropriateness of treatment.

Side Effects

For external use only. Patients should stop use and consult a doctor if discomfort persists or worsens. Additionally, individuals with diabetes or poor blood circulation are advised to seek medical advice before use.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Corn Remover (salicylic acid 40%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this medication for external application only. Care should be taken to avoid contact with the eyes or face. If discomfort persists or worsens, it is advised to stop use and consult a healthcare professional.

In children with diabetes or poor blood circulation, it is recommended to seek medical advice prior to use. In the event of accidental ingestion, immediate medical assistance should be sought or contact with a Poison Control Center is advised.

For application, the affected area should be washed thoroughly with warm water, and it may be beneficial to soak the wart for up to 5 minutes. After drying the area completely, the medicated plaster can be cut to fit the wart as necessary. The plaster should be applied and may be repeated every 48 hours as needed, for a maximum duration of 12 weeks.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should be aware that the safety of this medication during pregnancy has not been specifically established. There are no available data regarding the potential risks or fetal impacts associated with its use in this population. Healthcare professionals are advised to consider the lack of information when prescribing this medication to women of childbearing potential and to weigh the potential benefits against any unknown risks. It is recommended that healthcare providers discuss the implications of medication use during pregnancy with their patients, ensuring informed decision-making.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, there is currently no specific information available regarding the effects or management of such an occurrence. Healthcare professionals are advised to monitor the patient closely for any unusual symptoms and to provide supportive care as necessary.

Given the absence of detailed guidance, it is recommended that healthcare providers consult local poison control centers or relevant medical authorities for further assistance in managing potential overdosage situations. Continuous assessment of the patient's condition is essential to ensure appropriate interventions are implemented promptly.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to fully evaluate the nonclinical toxicology profile.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important for patients to understand the seriousness of this situation and to act promptly.

Patients should be instructed to discontinue use and consult a doctor if they experience persistent or worsening discomfort. This guidance is crucial to ensure that any adverse reactions are appropriately addressed.

Additionally, healthcare providers should encourage patients to consult with a doctor if they have diabetes or poor blood circulation, as these conditions may influence the safety and efficacy of the product.

Providers must emphasize the importance of avoiding contact with the eyes or face. In the event that the product does come into contact with the eyes, patients should be advised to rinse thoroughly with water to mitigate any potential irritation or harm.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within the temperature range of 59°F to 86°F (15°C to 30°C) to ensure its efficacy and safety. Proper storage conditions must be maintained, and the product should be kept in a suitable container to protect it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's integrity.

Additional Clinical Information

The medicated plaster is administered topically and should be applied every 48 hours as needed, for a maximum duration of 12 weeks. Clinicians should counsel patients to avoid contact with the eyes or face; in the event of contact, the area should be rinsed thoroughly with water. Patients are advised to discontinue use and consult a doctor if discomfort persists or worsens. Additionally, individuals with diabetes or poor blood circulation should seek medical advice before use. In case of ingestion, immediate medical assistance or contact with a Poison Control Center is recommended.

Drug Information (PDF)

This file contains official product information for Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)